Our study suggests activating Fbxw7 as an anti-NASH therapy to break this vicious cycle by mitigating cellular stress and inhibiting apoptosis via direct control of the expression of its transcription factor targets. The gene discussed is FBXW7; the disease is metabolic dysfunction-associated steatohepatitis.